Home Newsfeeds Cowen & Co. Maintains Outperform on Oracle, Lowers Price Target to $96

Cowen & Co. Maintains Outperform on Oracle, Lowers Price Target to $96

Cowen & Co. analyst J. Derrick Wood maintains Oracle (NYSE:ORCL) with a Outperform and lowers the price target from $98 to $96.

byBenzinga Newsdesk

December 13, 2022

1 minute read

Cowen & Co. analyst J. Derrick Wood maintains Oracle (NYSE:ORCL) with a Outperform and lowers the price target from $98 to $96.

US-China Tensions Play Spoilsport For Huawei’s Malaysian Ambitions

By Anusuya Lahiri

May 2, 9:03 AM

The EU and U.S. have warned the Malaysian government against national security and foreign investment threat from awarding a 5G…

ERIC

Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter

By Vandana Singh

April 22, 12:36 PM

Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the upcoming medical conference in June.

CORT

JP Morgan Maintains Neutral on Deere, Lowers Price Target to $325

By Benzinga Newsdesk

July 12, 10:46 AM

JP Morgan analyst Tami Zakaria maintains Deere (NYSE:DE) with a Neutral and lowers the price target from $370 to $325.

BrightSpire Capital: Q2 Earnings Insights

By Benzinga Insights

August 3, 9:05 AM

BrightSpire Capital (NYSE:BRSP) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

BRSP

Cowen & Co. Maintains Outperform on Oracle, Lowers Price Target to $96

Related Posts

US-China Tensions Play Spoilsport For Huawei’s Malaysian Ambitions

Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter

JP Morgan Maintains Neutral on Deere, Lowers Price Target to $325

BrightSpire Capital: Q2 Earnings Insights